MY199045A - Poly-adp ribose polymerase (parp) inhibitors - Google Patents

Poly-adp ribose polymerase (parp) inhibitors

Info

Publication number
MY199045A
MY199045A MYPI2019003419A MYPI2019003419A MY199045A MY 199045 A MY199045 A MY 199045A MY PI2019003419 A MYPI2019003419 A MY PI2019003419A MY PI2019003419 A MYPI2019003419 A MY PI2019003419A MY 199045 A MY199045 A MY 199045A
Authority
MY
Malaysia
Prior art keywords
parp
poly
inhibitors
ribose polymerase
adp ribose
Prior art date
Application number
MYPI2019003419A
Other languages
English (en)
Inventor
Bharat Lagu
Taisuke Takahashi
Arthur Kluge
Nan Ji
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MY199045A publication Critical patent/MY199045A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019003419A 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors MY199045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440581P 2016-12-30 2016-12-30
PCT/US2017/068636 WO2018125961A1 (fr) 2016-12-30 2017-12-28 Inhibiteurs de la poly-adp-ribose polymérase (parp)

Publications (1)

Publication Number Publication Date
MY199045A true MY199045A (en) 2023-10-11

Family

ID=61007849

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003419A MY199045A (en) 2016-12-30 2017-12-28 Poly-adp ribose polymerase (parp) inhibitors

Country Status (33)

Country Link
US (2) US11034670B2 (fr)
EP (1) EP3562822B1 (fr)
JP (1) JP7141399B2 (fr)
KR (1) KR102606799B1 (fr)
CN (1) CN110167926B (fr)
AR (1) AR110706A1 (fr)
AU (1) AU2017388376B2 (fr)
CA (1) CA3047137A1 (fr)
CO (1) CO2019007906A2 (fr)
CY (1) CY1124565T1 (fr)
DK (1) DK3562822T3 (fr)
EA (1) EA201991412A1 (fr)
ES (1) ES2875841T3 (fr)
HR (1) HRP20210887T1 (fr)
HU (1) HUE054382T2 (fr)
IL (1) IL267676B (fr)
JO (1) JOP20190115B1 (fr)
LT (1) LT3562822T (fr)
MA (1) MA47165B1 (fr)
MD (1) MD3562822T2 (fr)
MX (1) MX393606B (fr)
MY (1) MY199045A (fr)
PH (1) PH12019501529A1 (fr)
PL (1) PL3562822T3 (fr)
PT (1) PT3562822T (fr)
RS (1) RS61895B1 (fr)
SA (1) SA519401894B1 (fr)
SI (1) SI3562822T1 (fr)
SM (1) SMT202100321T1 (fr)
TW (1) TWI773718B (fr)
UA (1) UA124777C2 (fr)
WO (1) WO2018125961A1 (fr)
ZA (2) ZA201904004B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333963C1 (en) * 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
PT3562822T (pt) * 2016-12-30 2021-06-02 Mitobridge Inc Inibidores de poli-adp ribose polimerase (parp)
JP7512380B2 (ja) * 2019-10-30 2024-07-08 ディグムバイオ.インコーポレイテッド イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ(adp-リボース)ポリメラーゼ-1(parp-1)関連疾患の予防又は治療用薬学的組成物
WO2022222921A1 (fr) * 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 Inhibiteur de parp contenant une structure de pipérazine, son procédé de préparation et son utilisation pharmaceutique
KR20240057402A (ko) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 그람 음성 박테리아 유출 펌프 억제제
CN113603630B (zh) * 2021-08-10 2023-06-27 苏州小栗医药科技有限公司 一种4-苯基哌啶盐酸盐的合成方法
KR20250065924A (ko) 2022-09-19 2025-05-13 바스프 에스이 아졸 살충 화합물
EP4617262A1 (fr) 2022-11-07 2025-09-17 Kyoto University Composé hétérocyclique contenant de l'azote
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024240108A1 (fr) * 2023-05-19 2024-11-28 上海海和药物研究开发股份有限公司 Inhibiteur de parp1 de type urée aryle, son procédé de préparation et son utilisation
CN117024357B (zh) * 2023-07-03 2026-02-24 山东第二医科大学 一种针对brca突变的选择性抑制剂及其用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025111705A1 (fr) * 2023-11-30 2025-06-05 Waverley Pharma Inc. Dérivés de quinazolinone utilisés en tant qu'inhibiteurs de poly (adp ribose) polymérase 1 (parp-1)
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
CN118084678B (zh) * 2024-03-01 2024-09-06 长沙唯楚医药科技有限公司 一种2-溴-6-氟苯胺的制备方法
WO2025217307A1 (fr) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies
TW202608867A (zh) * 2024-04-26 2026-03-01 美商雷密克斯醫療公司 用於降解週期蛋白k及抑制週期蛋白依賴性激酶之化合物及相關方法
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026030819A1 (fr) * 2024-08-08 2026-02-12 Waverley Pharma Inc. Dérivés de (3-hydroquinazolin-4-one) substitués et compositions pharmaceutiques de ceux-ci à utiliser comme inhibiteurs puissants et sélectifs de la poly [adp ribose] polymérase 1 (p arp-1) pour le traitement du cancer
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249262A1 (en) 2000-03-20 2001-10-03 Sepracor, Inc. Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
EP1272187B1 (fr) 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Ligands du recepteur d3 de la dopamine destines au traitement de la dependance
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
CA2557541C (fr) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Derives de pyrimidine
WO2006001463A1 (fr) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Composé ayant une activité de liaison aux récepteurs s1p et utilisation de celui-ci
CA2568835C (fr) * 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Derives de quinazolinone en tant qu'inhibiteurs de parp
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CN101263125A (zh) 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
EP2520567A3 (fr) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Dérivés d'hétérocycle contenant de l'azote substitués avec un groupe cyclique
WO2007110868A2 (fr) 2006-03-28 2007-10-04 Atir Holding S.A. Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels
WO2012064973A2 (fr) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et utilisations de ceux-ci
WO2012140642A1 (fr) 2011-04-10 2012-10-18 Atir Holding S.A. Composés hétérocycliques et leurs utilisations dans le traitement de troubles sexuels
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
EP2890696A1 (fr) * 2012-08-29 2015-07-08 Amgen, Inc. Composés quinazolinones et leurs dérivés
SG11201600743WA (en) 2013-07-31 2016-02-26 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
RU2016147727A (ru) 2014-05-07 2018-06-08 Мерк Патент Гмбх Гетероциклилбутанамидные производные
CN105924434A (zh) * 2015-02-28 2016-09-07 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2018026371A1 (fr) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc
PT3562822T (pt) * 2016-12-30 2021-06-02 Mitobridge Inc Inibidores de poli-adp ribose polimerase (parp)

Also Published As

Publication number Publication date
SMT202100321T1 (it) 2021-07-12
MA47165A (fr) 2019-11-06
PH12019501529A1 (en) 2020-09-14
HUE054382T2 (hu) 2021-09-28
KR20190098760A (ko) 2019-08-22
EP3562822B1 (fr) 2021-03-10
AU2017388376A1 (en) 2019-07-04
JP2020512298A (ja) 2020-04-23
HRP20210887T1 (hr) 2021-07-23
CN110167926A (zh) 2019-08-23
MA47165B1 (fr) 2021-06-30
LT3562822T (lt) 2021-06-10
CO2019007906A2 (es) 2019-10-21
AU2017388376B2 (en) 2022-01-06
ZA202003310B (en) 2021-08-25
AR110706A1 (es) 2019-04-24
CN110167926B (zh) 2022-09-13
ZA201904004B (en) 2022-12-21
MX2019007870A (es) 2019-08-16
CY1124565T1 (el) 2022-07-22
BR112019011676A2 (pt) 2019-10-15
US11993585B2 (en) 2024-05-28
US11034670B2 (en) 2021-06-15
US20220033380A1 (en) 2022-02-03
CA3047137A1 (fr) 2018-07-05
UA124777C2 (uk) 2021-11-17
WO2018125961A1 (fr) 2018-07-05
SA519401894B1 (ar) 2023-02-19
PT3562822T (pt) 2021-06-02
MX393606B (es) 2025-03-19
PL3562822T3 (pl) 2021-09-13
IL267676B (en) 2021-09-30
EA201991412A1 (ru) 2019-11-29
KR102606799B1 (ko) 2023-11-28
DK3562822T3 (en) 2021-05-03
MD3562822T2 (ro) 2021-07-31
NZ754385A (en) 2024-07-05
WO2018125961A8 (fr) 2019-05-23
EP3562822A1 (fr) 2019-11-06
ES2875841T3 (es) 2021-11-11
IL267676A (en) 2019-08-29
TW201834657A (zh) 2018-10-01
US20200071299A1 (en) 2020-03-05
JOP20190115B1 (ar) 2023-09-17
JOP20190115A1 (ar) 2019-05-20
RS61895B1 (sr) 2021-06-30
TWI773718B (zh) 2022-08-11
JP7141399B2 (ja) 2022-09-22
SI3562822T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
PH12019501529A1 (en) Poly-adp ribose polymerase (parp) inhibitors
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
PH12017501326A1 (en) Tgf-� inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
PH12017500580B1 (en) Pyrimidinones as factor xia inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
WO2011123946A8 (fr) Inhibiteurs de kinases et procédé de traitement du cancer utilisant ceux-ci
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
IN2015MN00002A (fr)
NZ746906A (en) Oxaborole esters and uses thereof
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX364400B (es) Compuestos de tetraciclina.
MX357763B (es) Tratamiento para cancer pancreatico.
EA202191885A3 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4